Clinical Trial Update: Centrally Acting ACE Inhibition in SLE [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on centrally acting ACE inhibition for Systemic Lupus Erythematosus; current status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Snippet

Sponsor: Northwell Health | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: ACTIVE_NOT_RECRUITING